New Bladder Cancer Enzyme Target Could Improve Treatment
Researchers identified an enzyme that helps bladder cancer resist chemotherapy, opening a new path for potential future treatments.
Updated on Oct. 24, 2026 in Cancer
Researchers have identified the USP3 enzyme as a primary driver of chemotherapy resistance in bladder cancer. By stabilizing the NPM1 protein, this enzyme helps cancer cells repair DNA damage, suggesting a new potential target for future treatments.
Why it matters
Chemoresistance is a major hurdle in treating bladder cancer, often leading to poor patient outcomes. This finding helps clarify why some tumors persist despite treatment and identifies a specific molecular target for potential drug development.
In a preclinical study, researchers found that USP3 is significantly upregulated in bladder cancer tissue and that silencing this enzyme inhibits tumor growth in vivo and in vitro. The results suggest the USP3-NPM1 signaling axis is a critical factor in promoting cancer cell survival.
The details
The USP3 enzyme acts by removing K48-linked polyubiquitination from the NPM1 protein, a process that stabilizes NPM1 and allows it to sustain nucleosome assembly. By maintaining this chromatin homeostasis, cancer cells can more effectively buffer against the DNA damage typically induced by cisplatin. This stabilization mechanism essentially shields the cancer from the intended effects of chemotherapy.
Timeline
October 24, 2026: Findings were published in a peer-reviewed research article.
Health Landscape
This finding contributes to the broader research effort investigating deubiquitinating enzyme inhibitors as a way to enhance traditional chemotherapy outcomes. It highlights how manipulating chromatin-stabilizing proteins could potentially overcome common pathways of drug resistance in cancer.
While this laboratory research is a promising early step, it is currently in a preclinical stage and not yet applicable to patient care decisions. If you are currently managing a cancer diagnosis, discuss the details of your treatment plan and potential for resistance with your oncologist.
The takeaway
The USP3 enzyme helps bladder cancer cells survive chemotherapy by stabilizing their DNA-repair machinery. Patients and caregivers should remain informed about evolving clinical research by maintaining regular, open communication with their oncology care team regarding new treatment options.
Further reading
For more on the current research landscape regarding aggressive malignancies, visit our Cancer section.
More information
You can review the full findings in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
